文献速递膀胱癌与上尿路尿路上皮癌

FGFR3突变激活可诱导管腔样乳头状膀胱肿瘤形成并促进男性性别偏倚

FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias.
PubMed 文献 · Eur Urol · 2022-10-21

研究构建表达最常见FGFR3突变(FGFR3-S249C)的转基因小鼠模型,发现该突变可在小鼠中诱导低级别乳头状膀胱癌,并促进BBN诱导的基底型膀胱癌形成;人类FGFR3突变肿瘤男性偏倚更显著,与AR活性较高、ESR1活性较低相关,突变FGFR3可抑制ESR1和AR活性。

要点

  • FGFR3-S249C表达可在小鼠中诱导低级别乳头状膀胱癌,组织学、基因组和转录组水平类似人类管腔样 counterpart。
  • 突变FGFR3表达水平影响小鼠肿瘤发生率,且突变FGFR3驱动的人类肿瘤局限于正常FGFR3高表达的上皮。
  • 人类FGFR3突变肿瘤男性偏倚高于野生型肿瘤,与AR活性较高和ESR1活性较低相关。

核心结论

  • 突变FGFR3启动管腔乳头状膀胱癌形成,并可能通过FGFR3依赖性ESR1下调促进膀胱癌男性性别偏倚。

研究设计与样本

  • 研究构建表达最常见FGFR3突变FGFR3-S249C的尿路上皮细胞转基因小鼠模型,监测有无致癌物暴露下的膀胱肿瘤发生,并比较小鼠与人类膀胱癌转录组数据。

主要发现

  • 小鼠尿路上皮表达FGFR3-S249C在组织学、基因组和转录组水平诱导类似人类管腔 counterpart 的低级别乳头状膀胱癌,并促进BBN诱导的基底型膀胱癌形成。
  • 突变FGFR3表达水平影响小鼠肿瘤发生率,且突变FGFR3驱动的人类肿瘤局限于正常FGFR3高表达的上皮。
  • 本模型中也发现膀胱癌男性性别偏倚,人类FGFR3突变肿瘤中该偏倚高于野生型肿瘤,并与AR活性较高和ESR1活性较低相关。
  • 突变FGFR3表达在小鼠肿瘤和人类细胞系中抑制ESR1和AR活性,仅证明FGFR3激活与肿瘤中低ESR1活性之间存在因果关系。

临床怎么用

  • 作者认为,癌前病变或早期膀胱癌患者可能从FGFR3靶向治疗中获益。
  • 作者认为,上皮中FGFR3表达水平可能解释FGFR3驱动癌的组织特异性。
  • 作者认为,结果可支持FGFR3突变的非侵入性检测及早期膀胱病变的FGFR3靶向治疗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Bladder cancer (BCa) is more common in men and presents differences in molecular subtypes based on sex. Fibroblast growth factor receptor 3 (FGFR3) mutations are enriched in the luminal papillary muscle-invasive BCa (MIBC) and non-MIBC subtypes. OBJECTIVE: To determine whether FGFR3 mutations initiate BCa and impact BCa male sex bias. DESIGN, SETTING, AND PARTICIPANTS: We developed a transgenic mouse model expressing the most frequent FGFR3 mutation, FGFR3-S249C, in urothelial cells. Bladder tumorigenesis was monitored in transgenic mice, with and without carcinogen exposure. Mouse and human BCa transcriptomic data were compared. INTERVENTION: Mutant FGFR3 overexpression in mouse urothelium and siRNA knockdown in cell lines, and N-butyl-N(4-hydroxybutyl)-nitrosamine (BBN) exposure. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Impact of transgene dosage on tumor frequency, synergy with BBN treatment, and FGFR3 pathway activation were analyzed. The sex-specific incidence of FGFR3-mutated tumors was evaluated in mice and humans. FGFR3 expression in FGFR3-S249C mouse urothelium and in various human epithelia was measured. Mutant FGFR3 regulation of androgen (AR) and estrogen (ESR1) receptor activity was evaluated, through target gene expression (regulon) and reporter assays. RESULTS AND LIMITATIONS: FGFR3-S249C expression in mice induced low-grade papillary BCa resembling human luminal counterpart at histological, genomic, and transcriptomic levels, and promoted BBN-induced basal BCa formation. Mutant FGFR3 expression levels impacted tumor incidence in mice, and mutant FGFR3-driven human tumors were restricted to epithelia presenting high normal FGFR3 expression levels. BCa male sex bias, also found in our model, was even higher in human FGFR3-mutated tumors compared with wild-type tumors and was associated with higher AR and lower ESR1 regulon activity. Mutant FGFR3 expression inhibited both ESR1 and AR activity in mouse tumors and human cell lines, demonstrating causation only between FGFR3 activation and low ESR1 activity in tumors. CONCLUSIONS: Mutant FGFR3 initiates luminal papillary BCa formation and favors BCa male sex bias, potentially through FGFR3-dependent ESR1 downregulation. Patients with premalignant lesions or early-stage BCa could thus potentially benefit from FGFR3 targeting. FGFR3 expression level in epithelia could account for FGFR3-driven carcinoma tissue specificity. PATIENT SUMMARY: By developing a transgenic mouse model, we showed that gain-of-function mutations of FGFR3 receptor, among the most frequent genetic alterations in bladder cancer (BCa), initiate BCa formation. Our results could support noninvasive detection of FGFR3 mutations and FGFR3 targeting in early-stage bladder lesions.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Shi MJ, Fontugne J, Moreno-Vega A, et al. FGFR3 Mutational Activation Can Induce Luminal-like Papillary Bladder Tumor Formation and Favors a Male Sex Bias. Eur Urol. 2022. PMID: 36273937. doi:10.1016/j.eururo.2022.09.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。